Carolyn M Yrigollen1, Laura Pacini2, Veronica Nobile2, Reymundo Lozano3, Randi J Hagerman4, Claudia Bagni5, Flora Tassone6. 1. Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, USA. 2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy. 3. Department of Pediatrics, University of California, Davis, USA. 4. Department of Pediatrics, University of California, Davis, USA; MIND Institute, University of California, Davis, USA. 5. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Italy; VIB Center for the Biology of Disease and Center for Human Genetics, Leuven, Belgium; Department of Fundamental Neuroscience, University of Lausanne, Lausanne, Switzerland. 6. MIND Institute, University of California, Davis, USA; Department of Biochemistry and Molecular Medicine, University of California, Davis, USA.
Abstract
OBJECTIVE: Fragile X syndrome (FXS) and tuberous sclerosis (TSC) are genetic disorders that result in intellectual disability and an increased prevalence of autism spectrum disorders (ASD). While the clinical presentation of each disorder is distinct, the molecular causes are linked to a disruption in the mTORC1 (mammalian Target of Rapamycin Complex 1) and ERK1/2 (Extracellular signal-Regulated Kinase) signaling pathways. METHODS: We assessed the clinical and molecular characteristics of an individual seen at the UC Davis MIND Institute with a diagnosis of FXS and TSC. Clinical evaluation of physical, behavioral, and cognitive impairments were performed. Additionally, total and phosphorylated proteins along the mTORC1 and ERK1/2 pathways were measured in primary fibroblast cell lines from the proband. RESULTS: In this case the phenotypic effects that result in a human with both FXS and TSC are shown to be severe. Changes in mTORC1 and ERK1/2 signaling proteins and global protein synthesis were not found to be noticeably different between four cohorts (typically developing, FMR1 full mutation, FMR1 full mutation and TSC1 loss of function mutation, and TSC1 loss of function mutation); however cohort sizes prevented stringent comparisons. CONCLUSION: It has previously been suggested that disruption of the mTORC1 pathway was reciprocal in TSC and FXS double knock-out mouse models so that the regulation of these pathways were more similar to wild-type mice compared to mice harboring a Fmr1-/y or Tsc2-/+ mutation alone. However, in this first reported case of a human with a diagnosis of both FXS and TSC, substantial clinical impairments, as a result of these two disorders were observed. Differences in the mTORC and ERK1/2 pathways were not clearly established when compared between individuals with either disorder, or both.
OBJECTIVE:Fragile X syndrome (FXS) and tuberous sclerosis (TSC) are genetic disorders that result in intellectual disability and an increased prevalence of autism spectrum disorders (ASD). While the clinical presentation of each disorder is distinct, the molecular causes are linked to a disruption in the mTORC1 (mammalian Target of Rapamycin Complex 1) and ERK1/2 (Extracellular signal-Regulated Kinase) signaling pathways. METHODS: We assessed the clinical and molecular characteristics of an individual seen at the UC Davis MIND Institute with a diagnosis of FXS and TSC. Clinical evaluation of physical, behavioral, and cognitive impairments were performed. Additionally, total and phosphorylated proteins along the mTORC1 and ERK1/2 pathways were measured in primary fibroblast cell lines from the proband. RESULTS: In this case the phenotypic effects that result in a human with both FXS and TSC are shown to be severe. Changes in mTORC1 and ERK1/2 signaling proteins and global protein synthesis were not found to be noticeably different between four cohorts (typically developing, FMR1 full mutation, FMR1 full mutation and TSC1 loss of function mutation, and TSC1 loss of function mutation); however cohort sizes prevented stringent comparisons. CONCLUSION: It has previously been suggested that disruption of the mTORC1 pathway was reciprocal in TSC and FXS double knock-out mouse models so that the regulation of these pathways were more similar to wild-type mice compared to mice harboring a Fmr1-/y or Tsc2-/+ mutation alone. However, in this first reported case of a human with a diagnosis of both FXS and TSC, substantial clinical impairments, as a result of these two disorders were observed. Differences in the mTORC and ERK1/2 pathways were not clearly established when compared between individuals with either disorder, or both.
Entities:
Keywords:
ERK1/2; Fragile X syndrome; Protein synthesis; Tuberous sclerosis; mTORC1
Authors: Walter E Kaufmann; Ranon Cortell; Alice S M Kau; Irena Bukelis; Elaine Tierney; Robert M Gray; Christiane Cox; George T Capone; Pia Stanard Journal: Am J Med Genet A Date: 2004-09-01 Impact factor: 2.802
Authors: Daman Kumari; Aditi Bhattacharya; Jeffrey Nadel; Kristen Moulton; Nicole M Zeak; Anne Glicksman; Carl Dobkin; David J Brick; Philip H Schwartz; Carolyn B Smith; Eric Klann; Karen Usdin Journal: Hum Mutat Date: 2014-12 Impact factor: 4.878
Authors: Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman Journal: Genome Med Date: 2012-12-21 Impact factor: 11.117